EU approves XOLREMDI as X4 Pharmaceuticals (NASDAQ: XFOR) reports Q1 loss
Filing Impact
Filing Sentiment
Form Type
10-Q
X4 Pharmaceuticals reported a Q1 2026 net loss of $20.2 million, reversing a small profit a year earlier as prior-year one-time license revenue from Norgine did not repeat. Total revenue was $2.7 million, including $2.5 million of U.S. XOLREMDI product sales and $0.2 million from its Norgine license.
Research and development expenses were $15.5 million and general and administrative expenses were $6.9 million, both down sharply following 2025 restructuring. X4 ended March 31, 2026 with $233.7 million in cash, cash equivalents and short-term marketable securities and $75.0 million of Hercules term debt.
During the quarter, X4 continued enrolling its global Phase 3 4WARD trial of mavorixafor in chronic neutropenia. On April 29, 2026, after quarter-end, the European Commission granted marketing authorization for XOLREMDI capsules to treat patients with WHIM syndrome in the European Union.
Positive
- European Commission approval: On April 29, 2026, the European Commission granted marketing authorization for XOLREMDI (mavorixafor) capsules for patients with WHIM syndrome in the European Union, adding a new commercial territory for the company’s lead product.
- Growing product revenue base: Net product sales of XOLREMDI rose to $2.5 million in Q1 2026 from $0.9 million a year earlier, reflecting increased U.S. patient uptake of the company’s first approved therapy.
- Strengthened cost structure and runway: Following 2025 restructuring, research and development and general and administrative expenses declined by a combined $11.1 million year over year, and X4 ended March 31, 2026 with $233.7 million in cash, cash equivalents and short-term marketable securities.
Negative
- None.
Insights
EU approval and rising XOLREMDI sales offset by continued losses.
X4 Pharmaceuticals is transitioning from a largely development-stage story toward a commercial model. Q1 2026 revenue was $2.7 million, driven mainly by U.S. XOLREMDI product sales of $2.5 million, while prior-year results were dominated by one-time Norgine license revenue.
The company recorded a net loss of $20.2 million as it funds the pivotal 4WARD trial in chronic neutropenia, with research and development expense of $15.5 million and general and administrative expense of $6.9 million. Cash, cash equivalents and short-term marketable securities totaled $233.7 million against Hercules term debt of $75.0 million, and management believes this supports operations for at least 12 months.
A key catalyst disclosed was the April 29, 2026 European Commission marketing authorization for XOLREMDI for WHIM syndrome, adding a second major geography for its lead asset. Future disclosures about EU launch progress and enrollment in the 4WARD trial through the end of Q3 2026 will help clarify the balance between commercial ramp and ongoing development spend.
Key Figures
Total revenue: $2.7M
Net product revenue (XOLREMDI): $2.5M
Net (loss) income: $(20.2)M
+5 more
8 metrics
Total revenue
$2.7M
Three months ended March 31, 2026
Net product revenue (XOLREMDI)
$2.5M
Three months ended March 31, 2026
Net (loss) income
$(20.2)M
Three months ended March 31, 2026
R&D expense
$15.5M
Three months ended March 31, 2026
G&A expense
$6.9M
Three months ended March 31, 2026
Cash, cash equivalents and short-term marketable securities
$233.7M
As of March 31, 2026
Hercules term debt principal
$75.0M
As of March 31, 2026; due July 1, 2027 with end-of-term payments
Shares outstanding
94,319,696 shares
Common stock outstanding as of May 1, 2026
Key Terms
accelerated approval, Fast Track designation, 4WARD trial, WHIM syndrome, +2 more
6 terms
accelerated approval regulatory
"XOLREMDI (mavorixafor), which has received accelerated approval in the United States from the FDA"
Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.
Fast Track designation regulatory
"The U.S. Food and Drug Administration ("FDA") has granted Fast Track designation to mavorixafor for the treatment of CN"
A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.
4WARD trial medical
"we continue to progress our global, pivotal Phase 3 clinical trial, (the "4WARD" trial) to evaluate the efficacy, safety, and tolerability"
WHIM syndrome medical
"XOLREMDI ... in patients 12 years of age and older with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome"
Hercules Loan Agreement financial
"we believe ... we will continue to comply with all covenants under the Hercules Loan Agreement, as defined and further described in Note 8"
chronic neutropenia medical
"people with congenital, acquired primary autoimmune, or idiopathic chronic neutropenia ("CN") who are experiencing recurrent and/or serious infections"
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
For the quarterly period ended March 31, 2026
or
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
For the transition period from __________ to __________
Commission File Number: 001-38295
_____________________________________________________________________________________
(Exact name of registrant as specified in its charter)
_____________________________________________________________________________________
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | ||||
(Address of principal executive offices) | (Zip Code) | ||||
(857 ) 529-8300
(Registrant’s telephone number, including area code)
____________________________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||||||||||
| ☒ | Smaller reporting company | |||||||||||||
| Emerging growth company | ||||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of May 1, 2026, the registrant had 94,319,696 shares of common stock, $0.001 par value per share, outstanding.
| X4 PHARMACEUTICALS INC. TABLE OF CONTENTS | ||||||||
PART I: FINANCIAL INFORMATION | Page | |||||||
Item 1: FINANCIAL STATEMENTS | 5 | |||||||
Condensed Consolidated Balance Sheets (unaudited) | 5 | |||||||
Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited) | 6 | |||||||
Condensed Consolidated Statements Stockholders’ Equity (unaudited) | 7 | |||||||
Condensed Consolidated Statements of Cash Flows (unaudited) | 8 | |||||||
Notes to Condensed Consolidated Financial Statements | 9 | |||||||
Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations | 22 | |||||||
Item 3: Quantitative and Qualitative Disclosures About Market Risk | 26 | |||||||
Item 4: Controls and Procedures | 26 | |||||||
PART II: OTHER INFORMATION | ||||||||
Item 1: Legal Proceedings | 28 | |||||||
Item 1A: Risk Factors | 28 | |||||||
Item 2: Unregistered Sales of Equity Securities and Use of Proceeds | 28 | |||||||
Item 3: Defaults upon Senior Securities | 28 | |||||||
Item 4: Mine Safety Disclosures | 28 | |||||||
Item 5: Other Information | 28 | |||||||
Item 6: Exhibits | 29 | |||||||
Signatures | 30 | |||||||
2
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
In this Quarterly Report on Form 10-Q, unless context otherwise requires or where otherwise indicated, the terms “X4” “we,”
“us,” “our,” and the “Company,” refer to X4 Pharmaceuticals, Inc. and its subsidiaries. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our plans, objectives, goals, strategies, future events, future operations, future financial position, future revenues or performance, projected costs, prospects, expectations, plans or intentions relating to clinical development, product candidates, the regulatory approval process, products and markets, and business trends and other information referred to in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” are forward-looking statements. In some cases, these statements may be identified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements and actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, including risks described in the section titled “Risk Factors” and elsewhere in this report, regarding, among other things:
•our ability to raise additional capital or achieve sufficient revenue to properly fund our business and operating plan as well as our ability to continue as a going concern;
•our expectations and goals for commercialization of XOLREMDI® (mavorixafor), which has been approved for use as an oral, once-daily therapy to increase the number of circulating mature neutrophils and lymphocytes in patients 12 years of age and older with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome in the U.S., and that XOLREMDI, our one product approved for commercial sale, upon which we depend almost entirely to produce revenue, faces an unknown market size and growth potential, and we have not generated significant revenue from product sales to date, and we may never achieve profitability;
•the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and related preparatory work and the period during which the results of the trials will become available, as well as our research and development programs;
•the potential benefits, including clinical utility, that may be derived from XOLREMDI or any of our product candidates;
•the timing of and our ability to obtain and maintain regulatory approval of our existing product XOLREMDI or any product candidates that we may develop in the future, and any related restrictions, limitations, or warnings in the label of any approved product candidates;
•our plans to research, develop, manufacture and commercialize XOLREMDI or our product candidates;
•the timing of our regulatory filings for our product candidates, along with regulatory developments in the United States and other foreign countries;
•the size and growth potential of the markets for XOLREMDI and our product candidates, if approved, and the rate and degree of market acceptance of XOLREMDI and our product candidates, including reimbursement that may be received from payors;
•the benefits of U.S. Food and Drug Administration (“FDA”) and European Commission designations, including, without limitation, Fast Track, Orphan Drug and Breakthrough Therapy;
•our commercialization, marketing and manufacturing capabilities and strategy;
•our ability to attract and retain qualified employees and key personnel;
3
•our competitive position and the development of and projections relating to our competitors or our industry;
•our expectations regarding our ability to obtain and maintain intellectual property protection;
•the success of competing therapies that are or may become available;
•our estimates and expectations regarding future operations, financial position, revenues, costs, expenses, uses of cash, capital requirements or our need for additional financing;
•our plans to in-license, acquire, develop and commercialize additional product candidates;
•the impact of laws and regulations;
•our plans to identify additional product candidates with significant commercial potential that are consistent with our commercial objectives;
•our strategies, prospects, plans, expectations or objectives; and
•other risks and uncertainties, including those listed under the section titled “Risk Factors” in this Quarterly Report.
You should refer to the section titled “Risk Factors” in Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2025 for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report.
4
PART I FINANCIAL INFORMATION
Item 1. Financial Statements.
X4 PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(unaudited)
| March 31, 2026 | December 31, 2025 | ||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | $ | |||||||||
| Accounts receivable | |||||||||||
| Marketable securities | |||||||||||
| Inventory | |||||||||||
| Prepaid expenses and other current assets | |||||||||||
| Total current assets | |||||||||||
| Property and equipment, net | |||||||||||
| Goodwill | |||||||||||
| Intangible asset, net | |||||||||||
| Right-of-use assets | |||||||||||
| Other assets | |||||||||||
| Total assets | $ | $ | |||||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | $ | |||||||||
| Accrued expenses | |||||||||||
| Deferred revenue | |||||||||||
| Current portion of lease liability | |||||||||||
| Total current liabilities | |||||||||||
| Long-term debt, including accretion, net of discount | |||||||||||
| Warrant liability | |||||||||||
| Deferred revenue | |||||||||||
| Other liabilities | |||||||||||
| Total liabilities | |||||||||||
| Commitments and contingencies (Note 10) | |||||||||||
| Stockholders’ equity: | |||||||||||
Preferred stock, $ | |||||||||||
Common stock, $ | |||||||||||
| Additional paid-in capital | |||||||||||
| Accumulated other comprehensive loss | ( | ( | |||||||||
| Accumulated deficit | ( | ( | |||||||||
| Total stockholders’ equity | |||||||||||
Total liabilities and stockholders’ equity | $ | $ | |||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5
X4 PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME
(In thousands, except share and per share amounts)
(unaudited)
| Three Months Ended March 31, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| License and other revenue | $ | $ | |||||||||||||||||||||
| Product revenue, net | |||||||||||||||||||||||
| Total revenue | |||||||||||||||||||||||
| Costs and operating expenses: | |||||||||||||||||||||||
| Cost of revenue | |||||||||||||||||||||||
| Research and development | |||||||||||||||||||||||
| General and administrative | |||||||||||||||||||||||
| Total operating expense | |||||||||||||||||||||||
| Loss from operations | ( | ( | |||||||||||||||||||||
| Other (expense) income, net: | |||||||||||||||||||||||
| Interest income | |||||||||||||||||||||||
| Interest expense | ( | ( | |||||||||||||||||||||
| Change in fair value of warrant liability | |||||||||||||||||||||||
| Other income, net | |||||||||||||||||||||||
| Total other income, net | |||||||||||||||||||||||
| (Loss) income before provision for income taxes | ( | ||||||||||||||||||||||
| Provision for income taxes | |||||||||||||||||||||||
| Net (loss) income | $ | ( | $ | ||||||||||||||||||||
Net (loss) income per share: basic | $ | ( | $ | ||||||||||||||||||||
Weighted average shares outstanding: basic | |||||||||||||||||||||||
| Net (loss) income per share: diluted | $ | ( | $ | ||||||||||||||||||||
| Weighted average shares outstanding: diluted | |||||||||||||||||||||||
| Other comprehensive (loss) income, net of tax: | |||||||||||||||||||||||
| Net (loss) income | $ | ( | $ | ||||||||||||||||||||
| Change in net unrealized gains on marketable debt securities | ( | ( | |||||||||||||||||||||
| Comprehensive (loss) income | $ | ( | $ | ||||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6
X4 PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands, except share amounts)
(Unaudited)
| Common Stock | Additional Paid-In Capital | Accumulated Other Comprehensive Loss | Accumulated Deficit | Total Stockholders’ Equity | |||||||||||||||||||||||||||||||
| Shares | Amount | ||||||||||||||||||||||||||||||||||
| Balance at December 31, 2024 | $ | $ | $ | ( | $ | ( | $ | ||||||||||||||||||||||||||||
| Vesting of restricted stock units | — | — | |||||||||||||||||||||||||||||||||
| Stock-based compensation expense | |||||||||||||||||||||||||||||||||||
| Unrealized loss on marketable securities | ( | ( | |||||||||||||||||||||||||||||||||
| Net income | |||||||||||||||||||||||||||||||||||
| Balance at March 31, 2025 | $ | $ | $ | ( | $ | ( | $ | ||||||||||||||||||||||||||||
| Common Stock | Additional Paid-In Capital | Accumulated Other Comprehensive Loss | Accumulated Deficit | Total Stockholders’ Equity | |||||||||||||||||||||||||||||||
| Shares | Amount | ||||||||||||||||||||||||||||||||||
| Balance at December 31, 2025 | $ | $ | $ | ( | $ | ( | $ | ||||||||||||||||||||||||||||
| Vesting of restricted stock units | — | — | |||||||||||||||||||||||||||||||||
| Exercise of prefunded warrants | ( | ||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | |||||||||||||||||||||||||||||||||||
| Unrealized loss on marketable securities | ( | ( | |||||||||||||||||||||||||||||||||
| Net loss | ( | ( | |||||||||||||||||||||||||||||||||
| Balance at March 31, 2026 | $ | $ | $ | ( | $ | ( | $ | ||||||||||||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7
X4 PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
| Three Months Ended March 31, | |||||||||||
| 2026 | 2025 | ||||||||||
| Cash flows from operating activities: | |||||||||||
| Net (loss) income | $ | ( | $ | ||||||||
| Adjustments to reconcile net (loss) income to net cash used in operating activities: | |||||||||||
| Stock-based compensation expense | |||||||||||
| Depreciation and amortization expense | |||||||||||
| Non-cash lease expense | |||||||||||
| Accretion of debt discount | |||||||||||
| Change in fair value of warrant liability | ( | ( | |||||||||
| Other | ( | ( | |||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable | ( | ||||||||||
| Inventory | ( | ( | |||||||||
| Prepaid expenses, other current and non-current assets | |||||||||||
| Accounts payable | ( | ||||||||||
| Accrued expenses and other long-term liabilities | ( | ( | |||||||||
| Deferred revenue | ( | ||||||||||
| Lease liabilities | ( | ( | |||||||||
| Net cash used in operating activities | ( | ( | |||||||||
| Cash flows from investing activities: | |||||||||||
| Acquisition of intangible asset | ( | ||||||||||
| Purchase of marketable securities | ( | ||||||||||
| Sales and maturities of marketable securities | |||||||||||
| Net cash provided by (used in) investing activities | ( | ||||||||||
| Cash flows from financing activities: | |||||||||||
| Proceeds from exercise of pre-funded warrants | |||||||||||
| Net cash provided by financing activities | |||||||||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | ( | ||||||||||
| Net decrease in cash, cash equivalents and restricted cash | ( | ( | |||||||||
| Cash, cash equivalents and restricted cash at beginning of period | |||||||||||
| Cash, cash equivalents and restricted cash at end of period | $ | $ | |||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
8
X4 PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Description of Business and Summary of Significant Accounting Policies
X4 Pharmaceuticals Inc., together with its subsidiaries (the “Company”), is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company continues to progress its global, pivotal Phase 3 clinical trial, (the “4WARD” trial) to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor (with or without stable doses of granulocyte colony-stimulating factor (“G-CSF”)) in people with congenital, acquired primary autoimmune, or idiopathic chronic neutropenia (“CN”) who are experiencing recurrent and/or serious infections. The 52-week trial is a randomized, double-blind, placebo-controlled, multicenter study aiming to enroll up to 176 patients, with full enrollment expected by the end of the third quarter of 2026. The U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to mavorixafor for the treatment of CN, which is defined as periods lasting more than three months persistently or intermittently where there are abnormally low levels of neutrophils circulating in the blood, and may be idiopathic (of unknown origin), cyclic (episodes typically occurring every three weeks), or congenital (of genetic causation). CN disorders are rare blood conditions similarly characterized by increased risks of infections and cancer due to abnormally low levels of neutrophils in the body. In all cases, the CXCL12/CXCR4 pathway is the key regulator of neutrophil release from the bone marrow. The Company has one commercially approved product, XOLREMDI ® (mavorixafor), which has received accelerated approval in the United States from the FDA for use as an oral, once-daily therapy in patients 12 years of age and older with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome, to increase the number of circulating mature neutrophils and lymphocytes. WHIM syndrome is a rare combined primary immunodeficiency and chronic neutropenic disorder. The Company is committed to making XOLREMDI available to patients in need in the U.S. while maintaining its focus on its long-term strategy to successfully complete the 4WARD trial in patients with moderate and severe CN. The Company is headquartered in Boston, Massachusetts.
Basis of Presentation
The accompanying unaudited interim condensed consolidated financial statements as of and for the three months ended March 31, 2026 and 2025, respectively have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and with the instructions to the Quarterly Report on Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company’s condensed financial position, condensed results of its operations and cash flows have been made. Operating results for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the entire year or for any other subsequent interim period.
These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2025 included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 17, 2026. The condensed consolidated balance sheet at December 31, 2025 that is presented in these interim condensed consolidated financial statements was derived from audited financial statements but does not include all disclosures required by GAAP.
Principles of Consolidation
The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including X4 Pharmaceuticals (Austria) GmbH, which is incorporated in Vienna, Austria, and X4 Therapeutics, Inc. All intercompany accounts and transactions have been eliminated.
Use of Estimates
The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the accrual of operational and financial license milestones, the accrual of reserves for variable consideration related to product revenue, and the impairment or lack of impairment of long-lived assets including operating lease right-of-use assets and goodwill. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the
9
X4 PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. As of the date of issuance of these condensed consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company’s condensed consolidated financial statements.
Liquidity
The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. Although the Company has an approved drug product, licensing and sales of the Company’s drug product over the next 12 months will not be sufficient to fund the Company’s operating expenses. Since inception, the Company has incurred significant operating losses and negative cash flows from operations, and the Company expects to continue to generate operating losses and negative cash flows from operations for the foreseeable future. For the three months ended March 31, 2026, the Company’s net loss was $20.2 million and net cash used in operating activities was $19.6 million. As of March 31, 2026, the Company had $233.7 million of cash, cash equivalents and short-term marketable securities, and an accumulated deficit of $614.8 million.
Based on its current operating plan, the Company believes (a) that its current cash, cash equivalents and short-term marketable securities will be sufficient to fund its operations for at least the next 12 months and (b) it will continue to comply with all covenants under the Hercules Loan Agreement, as defined and further described in Note 8, through at least the 12-month period from the issuance date of these condensed consolidated financial statements.
The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, uncertainties relating to conducting preclinical and clinical research and development, the manufacture and supply of products and product candidates for clinical and commercial use, obtaining and maintaining regulatory approvals and pricing and reimbursement for its products and product candidates, market acceptance, managing global growth and operating expenses, availability of additional capital, competition, obtaining and enforcing patents, stock price volatility, dependence on collaborative relationships and third-party service providers, dependence on key personnel, and from time to time government investigations, litigation, and potential product liability claims.
Significant Accounting Policies
The Company’s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 17, 2026. Since the date of those consolidated financial statements, there have been no material changes to the Company’s significant accounting policies.
Restricted Cash
| (in thousands) | As of March 31, 2026 | As of December 31, 2025 | |||||||||
| Letter of credit security: Vienna Austria lease | $ | $ | |||||||||
| Letter of credit security: Boston lease | |||||||||||
| Total restricted cash | $ | $ | |||||||||
In connection with the Company’s lease agreements for its facilities in Boston, Massachusetts, the Company maintains a letter of credit, which is secured by restricted cash, for the benefit of the respective landlord. As of December 31, 2025, restricted cash related to the Company’s former Vienna, Austria lease, which the Company terminated effective November 30, 2025, is included in other current assets and was subsequently converted to unrestricted cash during the three months ended March 31, 2026. Restricted cash related to the Boston lease is also included in other current assets.
In accordance with the Company’s Hercules Loan Agreement, the Company at all times must maintain a minimum level of cash of $15.0 million in an account or accounts in which Hercules has a first priority security interest.
10
X4 PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Cash, Cash Equivalents, Restricted Cash and Marketable Securities
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the total of amounts shown in the Company’s condensed consolidated statements of cash flows as of March 31, 2026 and December 31, 2025:
| (in thousands) | March 31, 2026 | December 31, 2025 | |||||||||||||||||||||
| Cash and cash equivalents | $ | $ | |||||||||||||||||||||
| Restricted cash, current (included within prepaid expenses and other current assets) | |||||||||||||||||||||||
| Total cash, cash equivalents and restricted cash | $ | $ | |||||||||||||||||||||
| Fair Value Measurements as of March 31, 2026 Using: | |||||||||||||||||||||||
| (in thousands) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
| Cash equivalents—money market funds | $ | $ | $ | $ | |||||||||||||||||||
| Marketable securities— U.S. Treasury notes, U.S. Treasury bills, and federal government agency notes | |||||||||||||||||||||||
| $ | $ | $ | $ | ||||||||||||||||||||
| Fair Value Measurements as of December 31, 2025 Using: | |||||||||||||||||||||||
| (in thousands) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
| Cash equivalents—money market funds | $ | $ | $ | $ | |||||||||||||||||||
| Marketable securities—U.S. Treasury notes, U.S. Treasury bills, and federal government agency notes | |||||||||||||||||||||||
| $ | $ | $ | $ | ||||||||||||||||||||
The following table provides amortized cost, unrealized gains and losses and the carrying amount of available-for-sale debt marketable securities as of March 31, 2026:
| (in thousands) | Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value | |||||||||||||||||||
| U.S. Treasury securities | $ | $ | $ | $ | |||||||||||||||||||
| Federal Government Agency securities | |||||||||||||||||||||||
| Total available-for-sale debt securities | $ | $ | $ | $ | |||||||||||||||||||
11
X4 PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
The following table provides amortized cost, unrealized gains and losses and the carrying amount of available-for-sale debt marketable securities as of December 31, 2025:
| (in thousands) | Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value | |||||||||||||||||||
| U.S. Treasury securities | $ | $ | $ | $ | |||||||||||||||||||
| Federal Government Agency securities | |||||||||||||||||||||||
| Total available-for-sale debt securities | $ | $ | $ | $ | |||||||||||||||||||
Liabilities Measured at Fair Value
The following tables present information about the Company’s financial liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:
| Fair Value Measurements as of March 31, 2026 Using: | |||||||||||||||||||||||
| (in thousands) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
| Liabilities: | |||||||||||||||||||||||
| Embedded derivative liability | $ | $ | $ | $ | |||||||||||||||||||
| Class C warrant liability | |||||||||||||||||||||||
| $ | $ | $ | $ | ||||||||||||||||||||
| Fair Value Measurements as of December 31, 2025 Using: | |||||||||||||||||||||||
| (in thousands) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
| Liabilities: | |||||||||||||||||||||||
| Embedded derivative liability | $ | $ | $ | $ | |||||||||||||||||||
| Class C warrant liability | |||||||||||||||||||||||
| $ | $ | $ | $ | ||||||||||||||||||||
The following table provides a roll-forward for the three months ended March 31, 2026 of the aggregate fair values of financial instruments for which fair values are determined using Level 3 inputs:
| (in thousands) | Embedded Derivative Liability | Class C Warrant Liability | Total | ||||||||||||||||||||||||||
| Balance as of December 31, 2025 | $ | $ | $ | ||||||||||||||||||||||||||
| Change in fair value | |||||||||||||||||||||||||||||
Balance as of March 31, 2026 | $ | $ | $ | ||||||||||||||||||||||||||
12
X4 PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Class C Warrant Liability— In December 2022, the Company issued Class C Warrants for the purchase of shares of its common stock in a public offering. The Class C Warrants are accounted for as a liability on the condensed consolidated balance sheet and are adjusted to fair value at period end through “change in fair value of warrant liability” on the condensed consolidated statements of operations and comprehensive (loss) income.
The Company calculated the fair value of the Class C Warrants using the Black-Scholes option pricing model, with the following inputs:
March 31, 2026 | December 31, 2025 | |||||||||||||
| Common stock price | $ | $ | ||||||||||||
| Risk-free interest rate | % | % | ||||||||||||
| Expected term (in years) | ||||||||||||||
| Expected volatility | % | % | ||||||||||||
| Expected dividend yield | % | % | ||||||||||||
Net (Loss) Income Per Share
Basic and diluted net (loss) income per share was calculated as follows:
| Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||
| (in thousands, except share and per share data) | 2026 | 2025 | |||||||||||||||||||||||||||||||||
| Numerator: | |||||||||||||||||||||||||||||||||||
Net (loss) income | $ | ( | $ | ||||||||||||||||||||||||||||||||
| Denominator: | |||||||||||||||||||||||||||||||||||
Weighted average shares outstanding—basic | |||||||||||||||||||||||||||||||||||
Net (loss) income per share— basic | $ | ( | $ | ||||||||||||||||||||||||||||||||
| Effective of dilutive securities | |||||||||||||||||||||||||||||||||||
| Time-based restricted stock units | |||||||||||||||||||||||||||||||||||
| Employee stock purchase plan | |||||||||||||||||||||||||||||||||||
| Dilutive potential common shares | |||||||||||||||||||||||||||||||||||
Weighted average shares outstanding-—diluted | |||||||||||||||||||||||||||||||||||
Net (loss) income per share— diluted | $ | ( | $ | ||||||||||||||||||||||||||||||||
Basic and diluted weighted average shares of common stock outstanding for the three months ended March 31, 2026 and 2025 includes the weighted average effect of pre-funded warrants for the purchase of shares of common stock, for which the remaining unfunded exercise price is less than or equal to $0.03 per share.
For the three months ended March 31, 2026, during which the Company recorded net loss, the Company’s potentially dilutive securities included outstanding stock options, unvested restricted stock units and warrants to purchase shares of common stock. These potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share, and thus they are considered “anti-dilutive.” Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same for this period.
For the three month period ended March 31, 2025, during which the Company recorded net income, the dilutive effect of outstanding stock options, restricted stock units, employee stock purchase plan shares and warrants were calculated using the treasury stock method, whereby all such awards were assumed to be exercised at the beginning of the period. The hypothetical proceeds from such exercises, including the average unrecognized stock compensation expense for outstanding stock options
13
X4 PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
and restricted stock units, were assumed to be used to purchase outstanding common stock at the average price during the period. The net share impact of dilutive securities was added to the weighted average basic common shares outstanding to calculate weighted average diluted shares outstanding.
The Company excluded the following potential shares of common stock from the computation of diluted net (loss) income per share for the periods indicated because including them would have had an anti-dilutive effect:
| Three Months Ended March 31, | ||||||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | ||||||||||||||||||||||||
| Options to purchase shares of common stock | ||||||||||||||||||||||||||
| Unvested restricted stock units | ||||||||||||||||||||||||||
Warrants to purchase shares of common stock (excluding prefunded warrants, which are included in basic shares outstanding) | ||||||||||||||||||||||||||
Recently Issued Accounting Standards Not Yet Adopted
2. Strategic Restructuring Liability
In 2025, the Company implemented two strategic restructuring actions designed to sharpen operational focus and align resources with the Company’s long‑term strategy to successfully complete the 4WARD trial in patients with moderate and severe CN. These strategic restructuring actions resulted in an approximately 65 % reduction in employee headcount.
The following table summarizes the Company’s liability recognized in connection with severance benefits incurred under strategic restructuring initiatives:
| (in thousands) | ||||||||
| Balance as of January 1, 2026 | $ | |||||||
| Severance and other employee-related expenses (included in general and administrative expense) | ||||||||
| Cash payments | ( | |||||||
| Balance as of March 31, 2026 (included in accrued expenses) | $ | |||||||
3. Revenue
Product Revenue, Net
During the three months ended March 31, 2026, the Company recorded net revenue $2.5 million for the sale of the Company’s drug product in the U.S. Net product revenue was $0.9 million for the three months ended March 31, 2025.
14
X4 PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
The following table summarizes the balances and activity in each of the product reserve accounts for the three months ended March 31, 2026.
| (in thousands) | Rebates and Discounts | Co-Pay Assistance | Product Returns | Total | |||||||||||||||||||
| Beginning balance at December 31, 2025 | $ | $ | $ | $ | |||||||||||||||||||
| Provision related to revenue associated with sales processed in the three month period ended March 31, 2026 | |||||||||||||||||||||||
| Adjustments related to revenue associated with sales processed in prior periods | |||||||||||||||||||||||
| Credits and payments made during the period | ( | ( | ( | ||||||||||||||||||||
| Balance as of March 31, 2026 | $ | $ | $ | $ | |||||||||||||||||||
The provision for contractual discounts provided to the Company’s customer is recorded as a reduction of accounts receivable. The provisions for co-pay assistance payments, contractual rebates and product returns are classified within accrued expenses.
The following table provides a rollforward of accounts receivable for the three months ended March 31, 2026.
| (in thousands) | Accounts Receivable | ||||
| Beginning balance at December 31, 2025 | $ | ||||
| Increase in accounts receivable for drug product sales | |||||
| Decrease in accounts receivable for cash collections | ( | ||||
| Balance as of March 31, 2026 | $ | ||||
License and Other
During the first quarter of 2025, the Company entered into a license and supply agreement (the “Norgine Agreement”) with Norgine Pharma UK Ltd. (“Norgine”). The Company analyzed the activities required under the Norgine Agreement and concluded that the arrangement was indicative of a vendor-customer relationship and would be accounted for under ASC 606. To date, the Company has received a one-time, non-refundable, up-front payment of €28.5 million and a regulatory milestone payment of €0.5 million, which are included the transaction price. All other future regulatory-based milestone payments, which represent variable consideration, have been fully constrained as these are not yet considered probable. The Company has also excluded from the transaction price future royalty payments that are based on units sold by Norgine and future cumulative revenue-based milestone payments under the applicable practical expedient.
Under the Norgine Agreement, the Company’s promises include a) the delivery of a license, b) research and development services for certain components of WHIM clinical studies, c) research and development services for the global Phase 3 trial of XOLREMDI for CN, and d) the option for delivery of commercial drug supply.
The following table summarizes the allocation of transaction price to the performance obligations under the Norgine Agreement based on the weighting of estimated stand-alone selling price for these performance obligations at the inception of the agreement.
| Allocation of Transaction Price | Revenue Recognized | ||||||||||||||||||||||||||||
| (in thousands) | Three Months Ended March 31, | ||||||||||||||||||||||||||||
| Performance Obligation: | 2026 | 2025 | |||||||||||||||||||||||||||
| License | $ | $ | $ | ||||||||||||||||||||||||||
| Research and development services: WHIM | |||||||||||||||||||||||||||||
| Research and development services: CN | |||||||||||||||||||||||||||||
| Drug product supply | |||||||||||||||||||||||||||||
| Total | $ | $ | $ | ||||||||||||||||||||||||||
15
X4 PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
The following table provides a rollforward of deferred revenue three months ended March 31, 2026.
| (in thousands) | Deferred Revenue | ||||
| Beginning balance at December 31, 2025 | $ | ||||
| Decrease in deferred revenue for revenue recognized | ( | ||||
| Balance as of March 31, 2026 | $ | ||||
As of March 31, 2026, deferred revenue related to the Norgine Agreement was $1.0 million, of which $0.9 million was current.
4. Inventory
Inventory consists of the following:
| (in thousands) | March 31, 2026 | December 31, 2025 | |||||||||
| Raw materials | $ | ||||||||||
| Work in process | |||||||||||
| Finished goods | |||||||||||
| Total inventory | $ | $ | |||||||||
5. Property and Equipment
Property and equipment, net consisted of the following:
| (in thousands) | March 31, 2026 | December 31, 2025 | |||||||||
| Leasehold improvements | $ | $ | |||||||||
| Furniture and fixtures | |||||||||||
| Computer equipment | |||||||||||
| Lab equipment | |||||||||||
| Less: Accumulated depreciation | ( | ( | |||||||||
| $ | $ | ||||||||||
Depreciation expense related to property and equipment was approximately $36 thousand and $289 thousand for the three months ended March 31, 2026 and 2025, respectively.
6. Intangible Assets, Net
As of March 31, 2026, the Company’s net definite-lived intangible assets, which is comprised of the capitalization of certain milestone payments made or accrued related to its license agreement for the intellectual property contained in its drug product, included a gross intangible asset of $10.5 million, less accumulated amortization of $1.4 million for a net intangible asset of $9.1 million. The Company amortizes the intangible asset to cost of revenue over the remaining life of the underlying patent protecting the intellectual property through 2038.
As of March 31, 2026, amortization expense for the next five years and beyond is summarized as follows (in thousands):
| Year | Amortization expense | ||||
| 2026 (remainder of year) | |||||
| 2027 | |||||
| 2028 | |||||
16
X4 PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
| 2029 | |||||
| 2030 | |||||
Thereafter | |||||
Total | $ | ||||
7. Accrued Expenses
Accrued expenses consisted of the following:
| (in thousands) | March 31, 2026 | December 31, 2025 | |||||||||
| Accrued employee compensation and benefits | $ | ||||||||||
| Accrued external research and development expenses | |||||||||||
| Accrued royalty and milestone payments | |||||||||||
| Accrued professional fees | |||||||||||
| Other | |||||||||||
| $ | $ | ||||||||||
8. Long-Term Debt
Long-term debt consisted of the following:
| (in thousands) | March 31, 2026 | December 31, 2025 | |||||||||
| Principal amount of long-term debt | $ | $ | |||||||||
| Debt discount, net of accretion | ( | ( | |||||||||
| Cumulative accrual of end of term payments | |||||||||||
| Long-term debt | $ | $ | |||||||||
Hercules Loan Agreement
The Company is party to the Second Amended and Restated Loan and Security Agreement, as amended, (the “Hercules Loan Agreement”) with Hercules Capital Inc., which provides for an aggregate term loan facility of up to $107.5 million, under which the Company has borrowed an aggregate of $75.0 million of term loans, representing the maximum borrowings allowable as of March 31, 2026. The Hercules Loan Agreement is described in Note 11 to the consolidated financial statements contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 17, 2026.
The Company recognized interest expense under the Hercules Loan Agreement as follows:
| (in thousands) | Three Months Ended March 31, | ||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| Total interest expense | $ | $ | |||||||||||||||||||||
| Non-cash interest expense | $ | $ | |||||||||||||||||||||
The annual effective interest rate on the Hercules Loan Agreement as of March 31, 2026 was 11.2 %. There were no
17
X4 PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
March 31, 2026, future principal and accrued end-of-term payments of $76.9 million under the Hercules Loan Agreement are due on July 1, 2027.
9. Leases
The Company has a lease agreement for its facility in Boston, Massachusetts, which is the Company’s principal executive office. There are no restrictions or financial covenants associated with this lease agreement. The Company had an operating lease for approximately 1,200 square meters of laboratory and office space in Vienna, Austria that commenced in February 2021 for a term of seven years . Effective November 30, 2025, the Company terminated the lease in accordance with a lease amendment entered into with the landlord. Accordingly, the Company accelerated the amortization of the right-of-use asset to zero and adjusted the remaining lease obligation to zero as of December 31, 2025.
The components of lease expense for the three months ended March 31, 2026 and 2025 were as follows:
| (dollars in thousands) | Three Months Ended March 31, | ||||||||||||||||||||||||||||||||||
| Lease Cost | 2026 | 2025 | |||||||||||||||||||||||||||||||||
| Fixed operating lease cost | $ | $ | |||||||||||||||||||||||||||||||||
| Total lease expense | $ | $ | |||||||||||||||||||||||||||||||||
| Other information | |||||||||||||||||||||||||||||||||||
| Operating cash outflows from operating leases | $ | ||||||||||||||||||||||||||||||||||
| Weighted-average remaining lease term—operating leases | |||||||||||||||||||||||||||||||||||
| Weighted-average discount rate—operating leases | % | % | |||||||||||||||||||||||||||||||||
Maturities of lease liabilities due under lease agreements that have commenced as of March 31, 2026 are as follows (in thousands):
| Maturity of lease liabilities | Operating Leases | ||||
| 2026 (remainder of the year) | $ | ||||
| Total lease payments | |||||
| Less: interest | ( | ||||
| Total operating lease liabilities as of March 31, 2026 | $ | ||||
10. Commitments and Contingencies
The Company has agreements with contract research organizations (“CROs”) pursuant to which the Company and the CROs are conducting clinical trials. The Company may terminate these agreements by providing notice pursuant to the contractual provisions of such agreements and would incur early termination fees. The Company has agreements with contract manufacturing organizations (“CMOs”) for the production of mavorixafor for use in clinical trials and for the commercial supply of XOLREMDI. The Company’s agreement with the CMO who produces batches of drug substance for use in the Company’s clinical and commercial drug supply contains cancellation provisions that would require the Company to pay up to the full contract value upon cancellation. As of March 31, 2026, the Company has approximately $2.1 million of such commitments in place subject to cancellation provisions.
License Agreements
See Note 5 to the Company’s Annual Report on Form 10-K filed with the SEC on March 17, 2026 for a description of licensing agreements, which commit the Company to contingent milestone and royalty fees based on future operational events.
Indemnification Agreements
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners, and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company
18
X4 PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
to, among other things, indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification obligations. The Company is not currently aware of any indemnification claims and has no
Legal Proceedings
The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to any legal proceedings.
11. Equity Transactions
ATM Sales Agreement
The Company was a party to a Controlled Equity OfferingSM Sales Agreement (“ATM”), dated as of August 7, 2020, pursuant to which the Company offered and sold shares of its common stock through one or more investment banks. The Company sold $24.2 million of its common stock, net of offering costs, under the ATM. The Company terminated the ATM on March 30, 2026.
12. Stock-Based Compensation
As of March 31, 2026, there is an aggregate of approximately 1.4 million shares of common stock available for issuance under the Company’s equity incentive plans, including 0.1 million shares of common stock remain available for issuance under the Amended and Restated 2017 Employee Stock Purchase Plan.
Stock Option Valuation
The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted:
| Three Months Ended March 31, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
| Risk-free interest rate | % | % | |||||||||||||||||||||
| Expected term (in years) | |||||||||||||||||||||||
| Expected volatility | % | % | |||||||||||||||||||||
| Expected dividend yield | % | % | |||||||||||||||||||||
As of March 31, 2026, total unrecognized compensation expense related to unvested stock options and restricted stock units was $19.8 million, which is expected to be recognized over a weighted average period of 2.9 years.
19
X4 PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Stock Options
The following table summarizes the Company’s stock option activity for the three months ended March 31, 2026:
| Number of Shares | Weighted Average Exercise Price | Weighted Average Contractual Term (Years) | Aggregate Intrinsic Value (in thousands) | ||||||||||||||||||||
| Outstanding as of December 31, 2025 | $ | $ | |||||||||||||||||||||
| Granted | |||||||||||||||||||||||
| Forfeited and expired | ( | $ | |||||||||||||||||||||
| Outstanding as of March 31, 2026 | $ | $ | |||||||||||||||||||||
| Exercisable as of March 31, 2026 | $ | $ | |||||||||||||||||||||
| Vested and expected to vest as of March 31, 2026 | $ | $ | |||||||||||||||||||||
The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock to the extent the stock option had a lower exercise price. There were no options exercised in 2025 and 2024. The weighted average grant-date fair value per share of stock options granted during the three months ended March 31, 2026 and 2025 was $3.36 and $14.10 , respectively.
Restricted Stock Units
The following table summarizes the Company’s restricted stock unit activity for the three months ended March 31, 2026:
| Number of Shares | Weighted-Average Grant Date Fair Value | ||||||||||
| Unvested as of December 31, 2025 | $ | ||||||||||
| Vested | ( | ||||||||||
| Forfeited | ( | ||||||||||
| Unvested as of March 31, 2026 | $ | ||||||||||
Outstanding restricted stock units include performance-based restricted stock units (“PRSUs”), which will vest based on the achievement of an operational milestone. The Company considers the achievement of the remaining operational milestone related to outstanding PRSUs to be probable. Stock-based compensation expense has been recognized for these awards using the accelerated attribution model based on the fair value of the awards as of the date of grant and management’s best estimate of the date the probable operational milestone will be achieved. The Company updates its estimates related to the probability and timing of achievement of the operational milestones each period until the award either vests or is forfeited.
Stock-Based Compensation
Stock-based compensation expense was classified in the condensed consolidated statements of operations and comprehensive (loss) income as follows:
| Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | |||||||||||||||||||||||||||||||||
| Research and development expense | $ | $ | |||||||||||||||||||||||||||||||||
| General and administrative expense | |||||||||||||||||||||||||||||||||||
| Total stock-based compensation | $ | $ | |||||||||||||||||||||||||||||||||
13. Income Taxes
The Company did not record a material U.S. federal, state or international provision or benefit for income taxes in its condensed consolidated statement of operations and comprehensive (loss) income for the three months ended March 31, 2026 and 2025. The Company continues to maintain a valuation allowance against all remaining net deferred tax assets. The Company believes that it is more likely than not that it will not realize a future tax benefit of these attributes as the Company expects to continue to generate operating losses. Ultimate realization of any deferred tax asset is dependent on the Company’s ability to generate
20
X4 PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
14. Segment Information
The Company has defined its Chief Operating Decision Maker (“CODM”) as the Executive Chairman. The CODM manages the Company’s operations as a single operating segment, which comprises its single reportable segment, for the purposes of assessing performance and making operating decisions. The Company’s focus is on the research, development and commercialization of novel therapeutics for the treatment of rare diseases. The Company’s research, development and commercialization efforts are focused on its lead molecule, mavorixafor, which is being marketed in the U.S. under the trade name XOLREMDI. The CODM uses the Company’s condensed consolidated net (loss) income to monitor actual results as compared to forecast in assessing segment performance and allocation of resources.
The Company derives its revenue from the sale of XOLREMDI in the U.S. and from licensed rights and product sales of mavorixafor for other non-U.S. territories. The Company recognized $2.5 million and $0.9 million of revenue from its U.S. customer and $0.2 million and $27.9 million of revenue from a customer in the United Kingdom for the three months ended March 31, 2026 and 2025, respectively.
The measure of profit for the segment is net (loss) income and consisted of the following for the three months ended March 31, 2026, and 2025:
| Three Months Ended March 31, | |||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | |||||||||||||||||||||
| Revenue from external customers | $ | $ | |||||||||||||||||||||
| Compensation expense, excluding stock-based compensation, stock appreciation rights compensation expense and severance expense | |||||||||||||||||||||||
| Direct research and development program expenses (X4P-001, mavorixafor) | |||||||||||||||||||||||
| Other segment items (a) | |||||||||||||||||||||||
| Net (loss) income (measure of segment profit) | $ | ( | $ | ||||||||||||||||||||
The CODM only receives and reviews information regarding segment assets at the consolidated level. Certain other entity-wide disclosures are included elsewhere in these condensed consolidated financials statements. As of March 31, 2026, the Company’s single operating segment had long-lived assets, including property and equipment and right-of-use assets, of $1.2 million, which were located in the U.S. As of December 31, 2025, the operating segment’s long-lived assets were $1.6 million, all of which were located in the U.S.
15. Subsequent Events
MAA Approval
In January 2025, the European Medicines Agency (“EMA”) validated the Company’s Marketing Authorisation Application (“MAA”) for processing. On April 29, 2026, the European Commission granted marketing authorization for XOLREMDI® (mavorixafor) capsules for the treatment of patients with WHIM syndrome in the European Union.
21
Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and related notes in “Item 1. Financial Statements.” References in this report to “X4,” the “Company,” “we,” “our” and “us” are references to X4 Pharmaceuticals, Inc. and its subsidiaries.
Overview
We are a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. We continue to progress our global, pivotal Phase 3 clinical trial, (the “4WARD” trial) to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor (with or without stable doses of granulocyte colony-stimulating factor (“G-CSF”)) in people with congenital, acquired primary autoimmune, or idiopathic chronic neutropenia (“CN”) who are experiencing recurrent and/or serious infections. The 52-week trial is a randomized, double-blind, placebo-controlled, multicenter study aiming to enroll up to 176 patients, with full enrollment expected by the end of the third quarter of 2026. The U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to mavorixafor for the treatment of CN, which is defined as periods lasting more than three months persistently or intermittently where there are abnormally low levels of neutrophils circulating in the blood, and may be idiopathic (of unknown origin), cyclic (episodes typically occurring every three weeks), or congenital (of genetic causation). CN disorders are rare blood conditions similarly characterized by increased risks of infections and cancer due to abnormally low levels of neutrophils in the body. In all cases, the CXCL12/CXCR4 pathway is the key regulator of neutrophil release from the bone marrow.
We have one commercially approved product, XOLREMDI® (mavorixafor), which has received accelerated approval in the United States from the FDA for use as an oral, once-daily therapy in patients 12 years of age and older with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome, to increase the number of circulating mature neutrophils and lymphocytes. WHIM syndrome is a rare combined primary immunodeficiency and CN disorder. We are committed to making XOLREMDI available to patients in need in the U.S. while maintaining our focus on our long-term strategy to successfully complete the 4WARD trial in patients with moderate and severe CN.
Regulatory Update and Out-License Agreements
In January 2025, the EMA validated for processing our Marketing Authorization Application seeking regulatory approval to commercialize mavorixafor for WHIM syndrome in the European Union. On April 29, 2026, the European Commission granted marketing authorization for XOLREMDI® (mavorixafor) capsules for the treatment of patients with WHIM syndrome in the European Union.
Results of Operations
The following table summarizes the results of our operations for the three months ended March 31, 2026 and 2025:
| Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | 2026 | 2025 | Change | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue | $ | 2.7 | $ | 28.8 | $ | (26.1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Cost and operating expenses: | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cost of revenue | 0.6 | 4.7 | (4.1) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Research and development | 15.5 | 18.5 | (3.0) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| General and administrative | 6.9 | 15.0 | (8.1) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Total operating expenses | 23.0 | 38.2 | (15.2) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Loss from operations | (20.3) | (9.4) | (10.9) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Total other income, net | 0.1 | 9.7 | (9.6) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (Loss) income before income taxes | (20.2) | 0.3 | (20.5) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Provision for income taxes | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Net (loss) income | $ | (20.2) | $ | 0.3 | $ | (20.5) | |||||||||||||||||||||||||||||||||||||||||||||||
22
Revenue
Product Revenue, Net
Net product sales were $2.5 million and $0.9 million for the three months ended March 31, 2026 and 2025, respectively. Net product revenue growth over the prior year quarter was primarily due to an increase in the number of patients who have been prescribed the Company’s drug product. Gross-to-net adjustments were approximately 10% in the first quarter of 2026. Co-pay assistance payments and rebates to U.S. government payors have comprised the majority of our gross-to-net revenue adjustments.
License and Other
During the three months ended March 31, 2026, other revenue under our license and supply agreement (the “Norgine Agreement”) with Norgine Pharma UK Ltd. (“Norgine”) was comprised of $0.2 million for the provision of research and development services and delivery of drug product supply to Norgine. For the three months ended March 31, 2025, we recognized $27.6 million in license revenue in connection with the delivery of the license and $0.3 million for the provision of research and development services under the Norgine Agreement.
Operating Cost and Expenses:
Cost of Revenue
Cost of revenue primarily consists of amortization of an intangible asset related to accrued and paid milestone payments associated with our Genzyme license agreement, cost of manufacturing drug product sold, and sales-based or sublicense-based royalty payments due under our Genzyme license agreement. Cost of revenue decreased $4.1 million in the three months ended March 31, 2026, as compared to the same period in the prior year, primarily due to royalties in the prior year associated with sublicense income from our Norgine Agreement that did not reoccur in the current period.
Research and Development Expenses
Research and development expenses consist primarily of costs incurred in connection with the development of our product candidates, including employee salaries and related expenses, clinical development expenses, internal and third-party costs of manufacturing our drug products for use in our clinical trials. Research and development expenses also include costs related to compliance with regulatory requirements.
Following our strategic restructuring announced during the first quarter of 2025, substantially all of our research and development has been focused on our one product candidate, mavorixafor (X4P-001). The following table shows external costs incurred by product candidate (primarily external CRO costs) and unallocated research and development costs, primarily consisting of employee salaries and related expense for our research and development organization.
| Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||
| 2026 | 2025 | Change | |||||||||||||||||||||||||||||||||
| (in millions) | |||||||||||||||||||||||||||||||||||
| Direct research and development expenses by product candidate: | |||||||||||||||||||||||||||||||||||
| Mavorixafor (X4P-001) | $ | 10.4 | $ | 8.4 | $ | 2.0 | |||||||||||||||||||||||||||||
| Unallocated expense | 5.1 | 10.1 | (5.0) | ||||||||||||||||||||||||||||||||
| Total research and development expenses | $ | 15.5 | $ | 18.5 | $ | (3.0) | |||||||||||||||||||||||||||||
Research and development expenses decreased by $3.0 million in the three months ended March 31, 2026 as compared to the same period in the prior year. The decrease was primarily due to lower compensation and related benefit costs as a result of strategic restructuring actions implemented in 2025 partially offset by higher clinical costs as we continue to progress our 4WARD trial.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in executive, finance, and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor and public relations, accounting, and audit services.
General and administrative expenses decreased by $8.1 million in the three months ended March 31, 2026 as compared to the
23
same period in the prior year. The decrease was primarily due to a $4.0 million reduction in consulting fees, approximately $2.0 million in lower sales and marketing costs, $0.7 million of net reductions in compensation costs due to lower head count in general and administrative functions, and lower professional services costs in the current period as compared to the prior year.
Other Income (Expense), Net
| Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||
| 2026 | 2025 | change | |||||||||||||||||||||||||||||||||
| (in millions) | |||||||||||||||||||||||||||||||||||
| Interest income | $ | 2.1 | $ | 1.0 | $ | 1.1 | |||||||||||||||||||||||||||||
| Interest expense | (2.1) | (2.2) | 0.1 | ||||||||||||||||||||||||||||||||
| Change in fair value of Class C warrant liability | 0.1 | 10.8 | (10.7) | ||||||||||||||||||||||||||||||||
| Other income, net | — | 0.2 | (0.2) | ||||||||||||||||||||||||||||||||
| Total other income, net | $ | 0.1 | $ | 9.8 | $ | (9.7) | |||||||||||||||||||||||||||||
Other income, net, decreased approximately $9.7 million in the three months ended March 31, 2026 as compared to the same period in the prior year primarily due to lower gains in the current period on fair value adjustments related to our Class C warrants, partially offset by higher interest income on our marketable security investment portfolio.
Liquidity and Capital Resources
Sources of Liquidity
To date, we have funded our operations primarily with proceeds from sales of common stock, warrants and prefunded warrants for the purchase of our preferred stock and our common stock, sales of preferred stock, proceeds from the issuance of convertible debt and borrowings under loan and security agreements.
Public and Private Equity Offerings. Over the past several years, we have funded our operations from sales of common stock, warrants and prefunded warrants through both public offerings and private placements. For example, most recently in October 2025 we completed an underwritten public offering of approximately 52.8 million shares of our common stock and prefunded warrants to purchase up to 700,000 shares of our common stock for net proceeds of $145.6 million, after underwriting discounts and offering expenses.
ATM Sales Agreement. We were a party to a Controlled Equity OfferingSM Sales Agreement (“ATM”), dated as of August 7, 2020, pursuant to which we periodically sold shares of our common stock through one or more investment banks. We have sold $24.2 million of our common stock, net of offering costs, under the ATM. We terminated the ATM effective March 30, 2026.
Hercules Loan Agreement. We are a party to a loan and security agreement (the “Hercules Loan Agreement”), which provides for a term loan facility of up to $107.5 million, under which we have borrowed an aggregate of $75.0 million of term loans to date, representing the maximum borrowings as of March 31, 2026. The term loan facility requires that we make interest-only payments through maturity on July 1, 2027 and requires that we meet certain operational and financial covenants. See Note 11 to our Annual Report on Form 10-K as filed with the SEC on March 17, 2026 for a full description of our Hercules Loan Agreement.
24
Historical Cash Flows
The following table summarizes our cash flow activities for each of the periods presented:
| Three Months Ended March 31, | |||||||||||
| 2026 | 2025 | ||||||||||
| (in thousands) | |||||||||||
| Net (loss) income | $ | (20.2) | $ | 0.3 | |||||||
| Adjustments to reconcile net (loss) income to net cash used in operating activities | 3.0 | (9.4) | |||||||||
| Changes in operating assets and liabilities | (2.4) | (3.3) | |||||||||
| Net cash used in operating activities | (19.6) | (12.4) | |||||||||
| Net cash provided by (used in) investing activities | 19.3 | (3.1) | |||||||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (0.1) | — | |||||||||
| Net decrease in cash, cash equivalents and restricted cash | (0.4) | (15.5) | |||||||||
| Cash, cash equivalents and restricted cash, beginning of period | 217.9 | 56.5 | |||||||||
| Cash, cash equivalents and restricted cash, end of period | $ | 217.5 | $ | 41.0 | |||||||
Operating Activities
During the three months ended March 31, 2026, net cash used in operating activities was $19.6 million, primarily resulting from our net losses of $20.2 million. Net cash used in operating activities for the three months ended March 31, 2025 was $12.4 million, primarily resulting from operating expenses of approximately $38.2 million, approximately $2.5 million in severance and related payments, and $6.1 million for the payment of our annual bonuses, partially offset by license and net product sale receipts of $31.2 million and other changes in working capital.
Investing Activities
During the three months ended March 31, 2026, cash provided by investing activities of $19.3 million was primarily due to net sales of short-term marketable securities. During the three months ended March 31, 2025, cash used in investing activities of $3.1 million was due to net investment in short-term marketable securities.
Financing Activities
There were no significant cash flows from financing activities during the three months ended March 31, 2026 and 2025.
Capital Resources
Based on our cash, cash equivalents and marketable securities on hand as of May 6, 2026 and our current operating plan, we believe that our cash, cash equivalents and marketable securities will allow us to fund operations for at least the next 12 months.
Capital Requirements
We expect to continue to incur operating losses as we advance our lead drug candidate through the 4WARD trial. Until we reach profitability, we will need to raise additional capital, which cannot be assured, to fund our operations and meet our financial obligations beyond this period. Such additional capital could be raised through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements, or other collaborations and strategic alliances. If we are unable to obtain funding, we could be forced to delay, reduce, or eliminate some or all of our research and development programs, product portfolio expansion or commercialization efforts, which would adversely affect our business prospects, or we may be unable to continue operations and may need to restructure our obligations in a court-supervised process or otherwise.
Due to the numerous risks and uncertainties associated with the future sale of our approved drug product and the research, development, and commercialization of future product candidates, we are unable to estimate the exact amount of our funding requirements. Our short-term and long-term funding requirements will depend on and could increase significantly as a result of many factors, including:
•the scope, number, initiation, progress, timing, costs, design, duration, any potential delays, and results of clinical trials and nonclinical studies for our current or future product candidates, particularly our Phase 3 clinical trial of mavorixafor for the treatment of individuals with chronic neutropenic disorders;
•the outcome, timing and cost of regulatory reviews, approvals or other actions to meet regulatory requirements established by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or
25
comparable foreign regulatory authorities to require that we perform more studies for our product candidates than those that we currently expect;
•our ability to obtain marketing approval for our product candidates;
•the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights covering our product and product candidates, including any such patent claims and intellectual property rights that we have licensed from Genzyme pursuant to the terms of our license agreement with Genzyme;
•our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product or product candidates;
•our ability to establish and maintain licensing, collaboration or similar arrangements on favorable terms and whether and to what extent we retain development or commercialization responsibilities under any new licensing, collaboration or similar arrangement;
•the success of any other business, product or technology that we acquire or in which we invest;
•the costs of acquiring, licensing or investing in businesses, product candidates and technologies;
•the effect of competing technological and market developments; and
•the costs to continue operating as a public company.
CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES
Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.
During the three months ended March 31, 2026, there were no material changes to our critical accounting policies as reported for the year ended December 31, 2025 as part of our Annual Report on Form 10-K. See Note 1 to the unaudited interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q under the heading Recently Issued Accounting Standards Not Yet Adopted for new accounting pronouncements or changes to the accounting pronouncements during the three months ended March 31, 2026.
Smaller Reporting Company Status
We are a smaller reporting company (“SRC”) as defined by Rule 12b-2 of the Exchange Act and Item 10(f)(1) of Regulation S-K. We may take advantage of certain of the scaled disclosures available to smaller reporting companies for so long as (i) our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
As an SRC, we are not required to provide the information requested by this Item.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods
26
specified in the SEC’s rules and forms and accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.
Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March 31, 2026, and have concluded that, based on such evaluation, our disclosure controls and procedures were effective as of March 31, 2026 at the reasonable assurance level. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the three months ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
27
PART II: OTHER INFORMATION
Item 1. Legal Proceedings
From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results or financial condition.
Item 1A. Risk Factors
Our business is subject to various risks, including those described in Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes from the risk factors disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Rule 10b5-1 Trading Plans
During the quarter ended March 31, 2026, no director or Section 16 officer adopted terminated
28
Item 6. Exhibits
| Incorporated by Reference to: | ||||||||||||||||||||||||||||||||
| Exhibit No. | Exhibit Description | Form | Exhibit No. | Filing Date | File No. | |||||||||||||||||||||||||||
| 3.1 | Restated Certificate of Incorporation, as amended, as of September 1, 2022. | 8-K | 3.1 | 09/01/2022 | 001-38295 | |||||||||||||||||||||||||||
| 3.2 | Certificate of Amendment to the Restated Certificate of Incorporation of X4 Pharmaceuticals, Inc. | 8-K | 3.1 | 04/24/2025 | 001-38295 | |||||||||||||||||||||||||||
| 3.3 | Amended and Restated By-laws of the Company | 8-K | 3.2 | 11/20/2017 | 001-38295 | |||||||||||||||||||||||||||
| 4.1 | Form of Common Stock Certificate | 8-K | 4.1 | 3/13/2019 | 001-38295 | |||||||||||||||||||||||||||
| 31.1* | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |||||||||||||||||||||||||||||||
| 31.2* | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |||||||||||||||||||||||||||||||
| 32.1** | Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||||||||||||||||||||||||||||||
| 101.INS* | Inline XBRL Instance Document | |||||||||||||||||||||||||||||||
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |||||||||||||||||||||||||||||||
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |||||||||||||||||||||||||||||||
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |||||||||||||||||||||||||||||||
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | |||||||||||||||||||||||||||||||
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |||||||||||||||||||||||||||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | |||||||||||||||||||||||||||||||
* Filed herewith
** The certification attached as Exhibit 32.1 accompanying this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.
@ Indicates management contract or compensatory plan.
29
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| X4 PHARMACEUTICALS, INC. | ||||||||
| Date: May 6, 2026 | By: | /s/ Adam R. Craig | ||||||
Adam R. Craig, M.D., Ph.D., M.B.A. Executive Chairman (Principal Executive Officer) | ||||||||
| Date: May 6, 2026 | By: | /s/ David Kirske | ||||||
David Kirske Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer) | ||||||||
30
FAQ
How did X4 Pharmaceuticals (XFOR) perform financially in Q1 2026?
X4 Pharmaceuticals posted a Q1 2026 net loss of $20.2 million, compared with net income of $0.3 million a year earlier. Revenue was $2.7 million, mainly from $2.5 million in XOLREMDI product sales, while prior-year results were boosted by large, non-recurring license revenue.
What were X4 Pharmaceuticals (XFOR) revenues and key drivers in Q1 2026?
Total revenue was $2.7 million in Q1 2026, including $2.5 million of net product revenue from U.S. XOLREMDI sales and $0.2 million from research, development services and drug supply under the Norgine agreement. Prior-year revenue of $28.8 million was dominated by upfront license income.
What is X4 Pharmaceuticals’ cash position and debt level as of March 31, 2026?
X4 held $233.7 million in cash, cash equivalents and short-term marketable securities at March 31, 2026. Long-term debt under the Hercules Loan Agreement totaled $75.0 million in principal, with $76.9 million of principal plus end-of-term payments due on July 1, 2027.
How is X4 Pharmaceuticals (XFOR) progressing its 4WARD Phase 3 trial?
X4 continues its global pivotal Phase 3 4WARD trial of mavorixafor in chronic neutropenia. The 52-week, randomized, double-blind, placebo-controlled study plans to enroll up to 176 patients, with full enrollment expected by the end of the third quarter of 2026, subject to trial execution.
What recent regulatory milestones has X4 Pharmaceuticals achieved for XOLREMDI?
XOLREMDI has accelerated FDA approval in the U.S. and new EU authorization. It is approved for WHIM syndrome patients 12 and older in the U.S., and on April 29, 2026, the European Commission granted marketing authorization for XOLREMDI capsules to treat WHIM syndrome in the European Union.
How have X4 Pharmaceuticals’ operating expenses changed year over year?
Total operating expenses fell to $23.0 million in Q1 2026 from $38.2 million. Research and development declined by $3.0 million to $15.5 million, and general and administrative expenses decreased by $8.1 million to $6.9 million, reflecting 2025 restructuring and lower consulting, sales and marketing costs.